Immunogenicity and safety of different combinations involving a third booster dose of SARS-CoV-2 inactivated vaccine, inactivated quadrivalent influenza vaccine, and 23-valent pneumococcal polysaccharide vaccine in adults aged ≥60 years: a phase 4, r
Co-administration of the third dose of SARS-CoV-2 inactivated vaccine with the influenza vaccine, followed by PPV23, may be optimal for adults aged 18-59. In adults ≥60, all vaccine combinations were immunogenic, suggesting a flexible vaccination approach. Since antibody measurements were taken 28 days post-vaccination, ongoing surveillance is essential to assess the longevity of the immune responses.
Authors
- Wei Zhao (ORCID: https://orcid.org/0000-0002-7744-115X)
- Jian Wang (ORCID: https://orcid.org/0000-0003-1177-651X)
- Junnan Zhang
- Min Lv (ORCID: https://orcid.org/0000-0003-2962-2658)
- Ao Zhang (ORCID: https://orcid.org/0000-0001-7185-4642)
- Shanshan Zhou
- Shuang Bai (ORCID: https://orcid.org/0000-0002-2994-9768)
- Jiang Wu (ORCID: https://orcid.org/0000-0002-8505-4723)
- Weixin Chen (ORCID: https://orcid.org/0000-0003-4519-2790)
Institutions
- Beijing Center for Disease Prevention and Control (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-08-20
- DOI
- https://doi.org/10.3389/fimmu.2024.1437267
- Citations
- 5
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.95
Funders
- Beijing Municipal Science and Technology Commission